PwPepwise

MK-677 / Ibutamoren

Growth Hormone

Oral ghrelin mimetic (small molecule)

MK-677, also known as ibutamoren, is an orally active compound that stimulates the body's natural release of growth hormone (GH).

§Dosing at a glance

5 protocols · from the research
What it's forDoseHow oftenHowFor how long
Standard Adult Dose (Body Composition / GH Axis Stimulation)25 mgOnce dailyOralTaken by mouth.2 yrs
Elderly Populations25 mgOnce dailyOralTaken by mouth.24 mos
Bone Indications25 mgOnce dailyOralTaken by mouth.12–18 mos
Pediatric GH Deficiency (Investigational)0.8 mg/kg/day—OralTaken by mouth.—
Sleep Enhancement25 mg—OralTaken by mouth.7–14 days

Approximate values pulled from the research — double-check before dosing.

§01Summary

MK-677, also known as ibutamoren, is an orally active compound that stimulates the body's natural release of growth hormone (GH) by mimicking the hormone ghrelin. Unlike injectable GH, it works by activating the brain's own signaling pathway to produce GH in a pulsatile, physiologically normal pattern. Daily use at 25 mg consistently increases both GH and insulin-like growth factor-1 (IGF-1) levels, including restoring IGF-1 to ranges typical of younger adults in older populations4,2.

In clinical studies, MK-677 increases fat-free body mass compared to placebo2,7 and appears to improve nitrogen balance during periods of dietary restriction8, suggesting anti-catabolic properties. It increases bone turnover markers6,10 and may support bone mineral density at certain skeletal sites when combined with other therapies3. MK-677 has also been reported to improve sleep architecture, including increases in deep and REM sleep16. However, increases in fat-free mass have not consistently translated into improvements in muscle strength or physical function2,5, and the compound raises blood glucose and reduces insulin sensitivity in some users4,2,7. It is currently being investigated across multiple areas including age-related muscle loss, bone health, and metabolic conditions.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

MK-677 (ibutamoren mesylate) is a non-peptide, orally bioavailable small molecule that acts as a potent, selective agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a), also known as the ghrelin receptor. Unlike endogenous ghrelin (a 28-amino acid acylated peptide) or synthetic peptide secretagogues such as GHRP-6, MK-677's non-peptide structure confers resistance to proteolytic degradation, enabling oral administration and once-daily dosing4. Its mechanism is distinct from that of GH-releasing hormone (GHRH), as MK-677 activates a G-protein-coupled receptor pathway that amplifies GH secretory pulse amplitude and, to a lesser degree, pulse frequency, thereby preserving physiological pulsatility rather than inducing a continuous non-pulsatile GH secretion profile4,9.

Activation of GHSR-1a by MK-677 at the pituitary level enhances the sensitivity of somatotroph cells to endogenous GHRH, and at the hypothalamic level it may suppress somatostatin tone, together producing synergistic amplification of GH output4. This mechanism requires residual somatotroph function; in GH-deficient adults, the GH response to MK-677 correlated positively with baseline GH and IGF-1 levels (r=0.81 and 0.79, respectively), confirming that pituitary reserve is necessary for full drug effect11. In young healthy men, where somatotropic tone is already robust, total 24-hour GH secretion is not substantially augmented, but GH pulse frequency increases — reflecting redistribution rather than net amplification9.

Downstream of GH receptor activation, MK-677 drives hepatic IGF-1 synthesis, increasing serum IGF-1 and its primary binding protein IGFBP-3, which prolongs IGF-1 half-life and bioavailability4,2,8. IGF-1 mediates the observed anabolic effects on lean mass and nitrogen retention8, and the correlation between IGF-1 increases and osteocalcin changes (r=0.37, p<0.01) supports an IGF-1-dependent mechanism for bone turnover stimulation6. IGFBP-5, a positive modulator of IGF action in bone, is markedly elevated (43–44%) during MK-677 treatment10, providing an additional mechanistic pathway for skeletal anabolic effects.

Metabolically, GHSR-1a activation has counter-regulatory effects on insulin signaling: GH-induced lipolysis and reduced peripheral glucose uptake produce measurable insulin resistance, manifesting as increased fasting glucose4 and impaired oral glucose tolerance7. Cortisol elevations2 are inconsistently observed and appear to reflect GH-mediated stimulation of adrenocortical activity. The GH secretory response shows partial tachyphylaxis with continued dosing — peak GH values decline from day 1 to day 78 — yet downstream IGF-1 and anabolic markers remain durably elevated, indicating that the functional endpoint is maintained despite attenuation of peak GH pulses.

§04Evidence & efficacy

Evidence base
19Studies
16Human
0Animal

MK-677 robustly and consistently increases serum GH and IGF-1 levels across all studied populations — including healthy young adults, healthy elderly, obese individuals, GH-deficient adults, and GH-deficient children — confirming reliable pharmacodynamic target engagement4,9,11,12. IGF-1 levels are reliably restored to young-adult reference ranges in elderly subjects at 25 mg/day4,2.

In terms of body composition, MK-677 increases fat-free mass compared to placebo in healthy older adults2 and in obese subjects7, and reverses diet-induced nitrogen wasting8. However, these lean mass gains have not translated into improvements in muscle strength or physical function in adequately powered trials2,5.

For bone health, MK-677 consistently increases bone turnover markers across multiple populations6,10,3, and the combination of MK-677 plus alendronate may improve femoral neck bone mineral density beyond alendronate alone3. The overall bone density benefit across multiple skeletal sites, however, has not been demonstrated in a pivotal trial.

MK-677 has been reported to improve sleep architecture — increasing deep (stage IV) and REM sleep in both younger and older adults16 — and may reduce the LDL-C/HDL-C ratio in obese subjects13. Appetite stimulation appears as an early transient effect that subsides within months of continued use2.

In Alzheimer's disease, despite robust IGF-1 elevation confirming target engagement, MK-677 produced no significant effect on any of four primary clinical endpoints over 12 months1, indicating the IGF-1 axis stimulation does not modify disease progression in this indication.

§05Safety

MK-677 at 25 mg/day is generally tolerated in short-to-medium-term studies, with the most consistently reported concerns centered on metabolic parameters. Fasting blood glucose increases significantly — from approximately 5.4 to 6.8 mmol/L at 4 weeks in elderly subjects4 and by 0.3 mmol/L over 2 years in healthy older adults2 — and impaired glucose tolerance on oral glucose tolerance testing has been observed in obese subjects at both 2 and 8 weeks7. These findings indicate reduced insulin sensitivity, which is a meaningful concern in populations already at metabolic risk, including the elderly, obese individuals, and those with pre-diabetes.

Cortisol levels were elevated in some studies2 though transient and unaffected in others8,9, suggesting a variable and likely modest effect on the HPA axis. Prolactin increases have been observed7,9 but have remained within normal reference ranges. Total serum testosterone was reduced in one study in obese males, though free testosterone index was unchanged, suggesting a shift in binding protein levels rather than true androgen deficiency14.

Common side effects include transient increased appetite (typically resolving within months)2, mild lower-extremity edema2, and muscle pain2. A clinically serious safety signal — congestive heart failure in a subset of elderly hip fracture patients — led to early termination of one trial5, representing the most significant safety event in the clinical literature to date.

In GH-deficient children, short-term administration at 0.8 mg/kg/day produced no significant changes in glucose, insulin, prolactin, cortisol, or thyroid hormones12.

§06History

MK-677 was synthesized by Merck & Co. as part of a research program in the late 1980s and early 1990s aimed at developing orally active growth hormone secretagogues to address age-related somatotropic decline without the limitations of injectable GH therapy. It emerged from structure-activity relationship studies on peptide GH-releasing peptides (GHRPs), with the goal of creating a non-peptide mimic capable of surviving first-pass metabolism and achieving practical oral bioavailability. The compound was originally designated MK-677 and later named ibutamoren mesylate in reference to its mesylate salt formulation.

The first major human pharmacology studies were published in 1996, demonstrating dose-dependent GH and IGF-1 elevation in both healthy young adults9 and healthy elderly subjects4, establishing the core pharmacodynamic rationale for clinical development. Through the late 1990s, a series of studies characterized its metabolic, body composition, bone, and endocrine effects across multiple populations7,8,10,6. By the early 2000s, Merck pursued Phase II/III investigations in osteoporosis3, Alzheimer's disease1, hip fracture recovery5, and pediatric GH deficiency12.

Despite consistent pharmacodynamic target engagement, pivotal trials in Alzheimer's disease1 and hip fracture recovery5 did not demonstrate meaningful clinical benefit, and the hip fracture trial was terminated early due to a cardiovascular safety signal5. Merck did not advance MK-677 to regulatory approval in any indication. The compound has remained an active subject of academic investigation and has attracted widespread off-label interest in the sports performance and longevity communities, driving continued independent research into its effects on body composition, sleep, and aging.

§07References